Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor–positive human epidermal growth factor receptor 2–negative breast cancer: Primary results from TROPION-Breast01 Journal Article
| Authors: | Bardia, A.; Jhaveri, K.; Im, S. A.; Pernas, S.; De Laurentiis, M.; Wang, S.; Martínez Jañez, N.; Borges, G.; Cescon, D. W.; Hattori, M.; Lu, Y. S.; Hamilton, E.; Zhang, Q.; Tsurutani, J.; Kalinsky, K.; Rubini Liedke, P. E.; Xu, L.; Fairhurst, R. M.; Khan, S.; Denduluri, N.; Rugo, H. S.; Xu, B.; Pistilli, B.; for the TROPION-Breast01 Investigators |
| Article Title: | Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor–positive human epidermal growth factor receptor 2–negative breast cancer: Primary results from TROPION-Breast01 |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 3 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-01-20 |
| Start Page: | 285 |
| End Page: | 296 |
| DOI: | 10.1200/jco.24.00920 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl plus with full text |
| PMCID: | PMC11771365 |
| PUBMED: | 39265124 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF. |
